Novatim

Novatimm is a clinical-stage biotechnology company focused on developing novel immunotherapies for the treatment of infectious diseases and cancer. The company's lead program, TIMM-001, is a macrophage-targeted agent designed to modulate the immune system's response to chronic viral infections and malignant tumors. By specifically targeting macrophages, Novatimm aims to overcome the immune evasion mechanisms employed by pathogens like HIV and various solid tumors. The company's research is based on pioneering work in macrophage biology and its role in disease progression. Novatimm continues to advance its pipeline through early-stage clinical trials to validate its unique therapeutic approach.